152 related articles for article (PubMed ID: 12202904)
21. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
22. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Konjević G; Jović V; Jurisić V; Radulović S; Jelić S; Spuzić I
Clin Exp Metastasis; 2003; 20(7):647-55. PubMed ID: 14669796
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
24. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
25. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
Young MR; McCloskey G; Wright MA; Pak AS
Cancer Immunol Immunother; 1994 Jan; 38(1):9-15. PubMed ID: 8299123
[TBL] [Abstract][Full Text] [Related]
26. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma.
Strobbe LJ; Hart AA; Rümke P; Israels SP; Nieweg OE; Kroon BB
Melanoma Res; 1997 Dec; 7(6):507-12. PubMed ID: 9464624
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
28. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
Yang SC; Fry KD; Grimm EA; Roth JA
J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
30. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
[TBL] [Abstract][Full Text] [Related]
31. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
Stagg J; Lejeune L; Paquin A; Galipeau J
Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
[TBL] [Abstract][Full Text] [Related]
32. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
34. Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda MJ; Luistro L; Warrier RR; Wright RB; Hubbard BR; Murphy M; Wolf SF; Gately MK
J Exp Med; 1993 Oct; 178(4):1223-30. PubMed ID: 8104230
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
36. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
37. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
38. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
39. [Construction of an angiostatin eukaryotic expression vector and characterization of its inhibitory efficiency in B16 melanoma bearing mice].
Wang JS; Sun DJ; Guo LH; Lin GW; Fei J
Shi Yan Sheng Wu Xue Bao; 2002 Dec; 35(4):303-6. PubMed ID: 15346988
[TBL] [Abstract][Full Text] [Related]
40. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]